drug
methylphenidate hydrochloride ER
Marketedupdated 3mo agoby $COLL COLLEGIUM PHARMACEUTICAL, INC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval412 co-mentions · 201 sources
- drugMETADATE CD388 co-mentions · 206 sources
- drugMETADATE ER253 co-mentions · 206 sources
- drugRITALIN LA236 co-mentions · 206 sources
- drugQuillivant XR225 co-mentions · 206 sources
- drugMethylin224 co-mentions · 206 sources
- drugMETHYLIN ER224 co-mentions · 206 sources
- drugRelexxii214 co-mentions · 206 sources
all catalysts(0)
nothing on the calendar yet
Trials studying methylphenidate hydrochloride ER
- phase3Efficacy, Safety & Pharmacokinetic (PK) Study of HLD200 in Children Aged 4-5 Years With ADHD
- phase1Dexmethylphenidate Hydrochloride Tablets Under Fasting Conditions
- phase1Dexmethylphenidate Hydrochloride Tablets Under Non-Fasting Conditions
- phase4A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity
Patent cliff
source: FDA Orange Bookfirst barrier falls
Mar 23, 2032
~5.6 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (80)
- Mar 23, 2032formulationUS 10182995
- Mar 23, 2032formulationUS 10182995
- Mar 23, 2032formulationUS 10182995
- Mar 23, 2032formulationUS 10182995
- Mar 23, 2032formulationUS 10182995
- Mar 23, 2032method-of-use (U-2357)US 10292937
- Mar 23, 2032method-of-use (U-2357)US 10292937
- Mar 23, 2032method-of-use (U-2357)US 10292937
- Mar 23, 2032method-of-use (U-2357)US 10292937
- Mar 23, 2032method-of-use (U-2357)US 10292937
- Mar 23, 2032method-of-use (U-2357)US 10617651
- Mar 23, 2032method-of-use (U-2357)US 10617651
- Mar 23, 2032method-of-use (U-2357)US 10617651
- Mar 23, 2032method-of-use (U-2357)US 10617651
- Mar 23, 2032method-of-use (U-2357)US 10617651
- Mar 23, 2032method-of-use (U-2357)US 10881618
- Mar 23, 2032method-of-use (U-2357)US 10881618
- Mar 23, 2032method-of-use (U-2357)US 10881618
- Mar 23, 2032method-of-use (U-2357)US 10881618
- Mar 23, 2032method-of-use (U-2357)US 10881618
- Mar 23, 2032formulationUS 10905652
- Mar 23, 2032formulationUS 10905652
- Mar 23, 2032formulationUS 10905652
- Mar 23, 2032formulationUS 10905652
- Mar 23, 2032formulationUS 10905652
- Mar 23, 2032method-of-use (U-2357)US 11241391
- Mar 23, 2032method-of-use (U-2357)US 11241391
- Mar 23, 2032method-of-use (U-2357)US 11241391
- Mar 23, 2032method-of-use (U-2357)US 11241391
- Mar 23, 2032method-of-use (U-2357)US 11241391
- Mar 23, 2032formulationUS 11241392
- Mar 23, 2032formulationUS 11241392
- Mar 23, 2032formulationUS 11241392
- Mar 23, 2032formulationUS 11241392
- Mar 23, 2032formulationUS 11241392
- Mar 23, 2032method-of-use (U-2357)US 11911518
- Mar 23, 2032method-of-use (U-2357)US 11911518
- Mar 23, 2032method-of-use (U-2357)US 11911518
- Mar 23, 2032method-of-use (U-2357)US 11911518
- Mar 23, 2032method-of-use (U-2357)US 11911518
- Mar 23, 2032method-of-use (U-2357)US 8916588
- Mar 23, 2032method-of-use (U-2357)US 8916588
- Mar 23, 2032method-of-use (U-2357)US 8916588
- Mar 23, 2032method-of-use (U-2357)US 8916588
- Mar 23, 2032method-of-use (U-2357)US 8916588
- Mar 23, 2032formulationUS 8927010
- Mar 23, 2032formulationUS 8927010
- Mar 23, 2032formulationUS 8927010
- Mar 23, 2032formulationUS 8927010
- Mar 23, 2032formulationUS 8927010
- Mar 23, 2032formulationUS 9023389
- Mar 23, 2032formulationUS 9023389
- Mar 23, 2032formulationUS 9023389
- Mar 23, 2032formulationUS 9023389
- Mar 23, 2032formulationUS 9023389
- Mar 23, 2032method-of-use (U-2357)US 9028868
- Mar 23, 2032method-of-use (U-2357)US 9028868
- Mar 23, 2032method-of-use (U-2357)US 9028868
- Mar 23, 2032method-of-use (U-2357)US 9028868
- Mar 23, 2032method-of-use (U-2357)US 9028868
- Mar 23, 2032method-of-use (U-2357)US 9034902
- Mar 23, 2032method-of-use (U-2357)US 9034902
- Mar 23, 2032method-of-use (U-2357)US 9034902
- Mar 23, 2032method-of-use (U-2357)US 9034902
- Mar 23, 2032method-of-use (U-2357)US 9034902
- Mar 23, 2032formulationUS 9283214
- Mar 23, 2032formulationUS 9283214
- Mar 23, 2032formulationUS 9283214
- Mar 23, 2032formulationUS 9283214
- Mar 23, 2032formulationUS 9283214
- Mar 23, 2032formulationUS 9498447
- Mar 23, 2032formulationUS 9498447
- Mar 23, 2032formulationUS 9498447
- Mar 23, 2032formulationUS 9498447
- Mar 23, 2032formulationUS 9498447
- Mar 23, 2032method-of-use (U-2357)US 9603809
- Mar 23, 2032method-of-use (U-2357)US 9603809
- Mar 23, 2032method-of-use (U-2357)US 9603809
- Mar 23, 2032method-of-use (U-2357)US 9603809
- Mar 23, 2032method-of-use (U-2357)US 9603809
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 10m ago
Found something off?
comments(0)
5-min edit window · permanent after that